At 6.4% CAGR, the Europe Gastric Cancer Diagnostic Procedure Market is projected to be worth US$ 674.76 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Europe gastric cancer diagnostic procedure Market was valued at US$ 464.72 million in 2022 and is expected to reach US$ 674.76 million by 2028, registering a CAGR of 6.4 % from 2022 to 2028. Rise in Prevalence of Gastrointestinal Diseases and Surging Cases of Helicobacter Pylori Infection attributed to the Europe gastric cancer diagnostic procedure Market expansion.

Various studies in the past have established a relation between the colonization of the stomach with Helicobacter pylori (H. pylori) and the development of gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. According to a study “Current and Future Treatment of Helicobacter pylori Infections” in 2020, helicobacter pylori is considered to be the most common human pathogens and was estimated to infect ~50% of the world's population. The infection usually develops during infancy but remains asymptomatic, while long-standing clinical symptoms such as gastritis, peptic ulcer disease, and stomach cancer may be evident in the later stages of life. The World Health Organization (WHO) states that developing countries have a ~90% prevalence rate of H. pylori, whereas developed countries record a lower rate, i.e., ~50%. Moreover, it was significantly higher in adults than in children, i.e., 48.6% and 32.6%, respectively. Further, the prevalence of gastric diseases is significantly higher in the geriatric population as aging increases the risk of H. pylori infection. Increased age leads to thinning of the stomach lining, thus permitting the passage of bacteria through the protective lining, which contributes to their mobility and infection throughout the stomach. According to the WHO, the population of people aged 60 and above is expected to reach 13.7% by 2030. With such a projected rise in the geriatric population, the demand for primary care services, including screening, assessment, and management of clinical and functional comorbidities, is also increasing. Hence, the surging number of H. pylori cases boost the Europe gastric cancer diagnostic procedure market progress.

On the contrary, Shortage of Medical Laboratory Professionals hurdles the growth of Europe gastric cancer diagnostic procedure market progress.

Based on healthcare providers, the Europe gastric cancer diagnostic procedure market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The hospitals segment held 43.8 % market share in 2022, amassing US$ 203.34 million. It is projected to garner US$ 289.21 million by 2028 to expand at 6.0% CAGR during 2022–2028.

Based on symptoms type, the Europe gastric cancer diagnostic procedure market is segmented into symptomatic and asymptomatic. The Asymptomatic segment held 80.2% market share in 2022, amassing US$ 372.54 million. It is projected to garner US$ 536.09 million by 2028 to expand at 6.3% CAGR during 2022–2028.

Based on body fluid, the Europe gastric cancer diagnostic procedure market is segmented into body fluid blood, urine, saliva, stomach wash/gastric juice, tissue and others. Blood segment held 53.0% market share in 2022, amassing US$ 246.22 million. It is projected to garner US$ 365.55 million by 2028 to expand at 6.8% CAGR during 2022–2028.

Based on Diagnostic procedure, the Europe gastric cancer diagnostic procedure market is categorized into endoscopic procedure, biopsy and tissue tests, lab test, in-vitro diagnostic tests, imaging test, molecular diagnostics, multiplexing molecular diagnostics, immunoassay, and others. The imaging segment held 42.3% market share in 2022. It was assessed at US$ 196.54 million in 2022 and is likely to hit US$ 281.76 million by 2028, exhibiting a CAGR of 6.2% during the forecast period.

Based on offering, the Europe gastric cancer diagnostic procedure market is segmented into instruments, reagents & consumables and services. Reagents & Consumables segment held 49.3% market share in 2022, amassing US$ 229.09 million. It is projected to garner US$ 324.99 million by 2028 to expand at 6.0% CAGR during 2022–2028.

Based on disease condition, the Europe gastric cancer diagnostic procedure market is segmented into early gastric cancer and gastric cancer advanced types. The Gastric cancer advanced type segment held 79.7% market share in 2022, amassing US$ 370.41 million. It is projected to garner US$ 541.45 million by 2028 to expand at 6.5% CAGR during 2022–2028.

Based on country, The Europe gastric cancer diagnostic procedure market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest Of Europe.  Our regional analysis states that Germany captured 29.45 % market share in 2022. It was assessed at US$ 136.86 million in 2022 and is likely to hit US$ 194.26 million by 2028, exhibiting a CAGR of 6.0% during the forecast period.

Key players dominating the Europe gastric cancer diagnostic procedure market are Agilent Technologies Inc; Atlas-Link Biotech Co Ltd; BioMerieux SA; Bio-Rad Laboratories Inc; F. Hoffmann-La Roche Ltd; Illumina Inc; Myraid Genetics Inc; Thermo Fisher Scientific Inc; Vela Diagnostics Holding Pte Ltd among others.   

• In Mar-2022, Myriad Genetics launched Precise Oncology Solutions, a new suite of tests combining germline testing, tumor profiling, and companion diagnostic options, including evaluation for Homologous Recombination Deficiency (HRD), an important cancer repair pathway. The suite includes Myriad’s new Precise Tumor Molecular Profile Test, developed in collaboration with Intermountain Precision Genomics, other leading healthcare providers, and industry partners. 
• In Dec-2020, Thermo Fisher Scientific announced that it has signed an agreement with Janssen Biotech, Inc. to co-develop a companion diagnostic (CDx) in oncology. The CDx will support clinical trial enrollment globally. Under the agreement, Thermo Fisher Scientific will collaborate with Janssen Research & Development, LLC scientists to validate multiple biomarkers for use with Thermo Fisher's Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer (NSCLC). Additional indications in oncology may follow as part of the agreement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com